Navigation Links
Results of phase III study on Labopharm's novel antidepressant published in Psychiatry (Edgemont) Journal
Date:5/19/2009

ts with major unipolar depressive disorder (MDD).

The results of primary efficacy end point analyses demonstrated consistent statistical superiority of Labopharm's trazodone formulation over placebo. Moreover, statistically significant improvements were demonstrated on several secondary efficacy end points, including Hamilton Rating Scale for Depression (HAMD-17) responders, Montgomery-Asberg Depression Rating Scale (MADRS) score, and quality of sleep.

The authors emphasize the clinical importance of targeting sleep improvement in patients with MDD, which is reported in more than 90% of cases. Patients receiving Labopharm's trazodone formulation demonstrated significant improvements versus placebo in all three quality of sleep end points, with an improvement by the first week of therapy in "overall quality of sleep" and "awakening during the night".

Agitation is a common symptom of MDD and patients taking antidepressants often experience an exacerbation of this symptom. In the study, those administered Labopharm's trazodone formulation showed no increase in agitation.

The results of the study demonstrate Labopharm's once-daily trazodone may have a early onset of action. The overall antidepressant efficacy of Labopharm's trazodone formulation was accompanied by improvements early in the study, including an early improvement in HAMD-17 scores, which suggest that patients may see clinical benefit within the first 2 weeks of treatment, and a significantly greater number of HAMD-17 responders than placebo by the end of titration.

Adverse events of particular concern in the treatment of MDD are those related to weight gain and sexual dysfunction, as they are among the most prevalent reasons for discontinuation of antidepressant therapy. In the study, there were no significant changes in body weight in either those administered Labopharm's trazodone formulation or those administered placebo and there was a low incidence of sexual dy
'/>"/>

SOURCE Labopharm Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. International Isotopes Inc. Announces First Quarter 2009 Financial Results
2. Encision Reports Fourth Quarter and Fiscal Year 2009 Results
3. Uroplasty to Issue Fourth Fiscal Quarter and Full Year Results on June 4, 2009
4. BMP Sunstone Reports First Quarter 2009 Financial Results
5. Neurocrine Announces Full Year Results from 603 Study (Petal Study) of Elagolix for Treatment of Endometriosis Pain
6. Lotus Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results
7. Jiangbo Pharmaceuticals Reports Results for the Third Quarter of its Fiscal Year 2009
8. AdCare Health Systems, Inc. Turns Profitable; Reports 2009 First Quarter Earnings Results
9. Light Sciences Oncology Announces Results of Study on Immunotherapeutic Mechanism of Aptocine(TM), a Novel Light-Activated Drug Therapy for Cancer
10. Derma Sciences Reports First Quarter 2009 Results
11. NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... interviewed dating men and pick-up artists about their experiences of female beauty, women’s ... bodily concerns, including penis issues, as well as their relationships with other men, ...
(Date:9/1/2015)... ... ... every family has them. Whether it’s a morning routine, meal time routine or weekly ... Here are three reasons why routines can be beneficial for a child: , 1. ... implemented into a child’s schedule, they are able to anticipate what will happen next ...
(Date:9/1/2015)... ... September 01, 2015 , ... September is Baby Safety Month, ... safety labels and stickers to keep little ones' safety top of mind at all ... has a particular focus. According to the JPMA's Baby Safety Zone website, this year's ...
(Date:9/1/2015)... ... September 01, 2015 , ... Curly Hair Solutions™ is ... This highly anticipated partnership between Curly Hair Solutions™ and Trade Secrets allows for ... Torch and the Curly Hair Solutions™ team could not be more delighted to ...
(Date:8/31/2015)... (PRWEB) , ... September 01, 2015 , ... ... to eliminate chronic back pain – once required a long, arduous recovery. However, ... hospital stay, less pain, less blood loss and minimal muscle damage. These advantages ...
Breaking Medicine News(10 mins):Health News:Female Porn Director Explains Male Insecurities about Women in a New Book 2Health News:Back into the Swing of Things: How Family Routines Benefit Children 2Health News:Lightning Labels Can Help Make A Difference This Baby Safety Month 2Health News:Lightning Labels Can Help Make A Difference This Baby Safety Month 3Health News:Curly Hair Solutions™ Partners With Trade Secrets 2Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 2Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 3Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 4
... India have criticized the recent announcement of health ... ,Mr.Vinay Agarwal, Secretary of Indian medical Association // that ... of adding ayurveda, unani and homoeopathy subjects in the ... anybody,", ,He added: "The move would also lead ...
... stress can affect younger men with clogged arteries leading to ... in the current issue of Psychosomatic Medicine. However, women in ... tendencies, said the study., ,The researchers from University of ... of the carotid arteries, which supply blood to the head, ...
... The field of genetics has been undergoing a revolution ... common disorders and a huge amount of resources allocated ... ,This has not only added motivation to scientists working ... replace the existing knowledge with those acquired new. One ...
... bred a new kind of rat that will help them ... postmenopausal women that can lead to hypertension and heart failure., ... have created a better research rat by changing a single ... them to study salt-sensitivity in hypertension as well as explore ...
... way is a judgement to popularise smoking but a simple stating ... National Institutes of Health and the Centre for Disease Control, // ... fresh cause of concern for anti-smoking lobbies and doctors. As smoking ... says that people who smoke are less likely to visit the ...
... by new virus-induced diseases like bird flu and Japanese ... specialization in virology. The NIV and the Institute of ... would confer the degree jointly., ,"There is a ... outbreak. The course is intended to provide qualified virologists ...
Cached Medicine News:Health News:Launch Of India’s First Virology Course At Pun 2
(Date:8/31/2015)... , Aug. 31, 2015 With ... cytometry is experiencing a rise in active partnerships. ... in underdeveloped nations to quantitate CD4 cell markers ... Logo - http://photos.prnewswire.com/prnh/20150831/262206LOGO ... the Global Flow Cytometry Market ( http://www.frost.com/nf0e ), ...
(Date:8/31/2015)...  The departments of Drug and Alcohol Programs (DDAP) ... 90 to raise awareness for International Overdose Awareness Day ... Pennsylvania and help more Pennsylvanians with substance ... the Building Bridges to Recovery initiative. ... to a disease that is fully treatable, if given ...
(Date:8/31/2015)... Pharmacy, Inc. (NYSE: DPLO ), the nation,s largest independent ... & CEO, and Sean Whelan , CFO, will present ... and Mr. Whelan are scheduled to participate in the Wells ... on Wednesday, September 9, 2015 at 1:45 PM ET. ... participate in the Robert W. Baird 2015 Healthcare Conference in ...
Breaking Medicine Technology:Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 2Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 3Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 4Pennsylvania Departments of Drug & Alcohol Programs and Health Kick-off Second Annual Building Bridges to Recovery Initiative 2Diplomat to Participate in Upcoming Investor Conferences 2
... LOS ANGELES--(BUSINESS WIRE)--May 21, 2007 - Cougar Biotechnology,Inc. ... Phase,II data on the Company's prostate cancer drug ... Urological,Association (AUA) Annual Meeting, which is currently taking ... Dr. Timothy A.,Yap from the Cancer Research UK ...
... WIRE)--May 21, 2007 - Medical,professionals seeking to ... gram-negative pneumonia may have a new weapon:,NKTR-061 ... by Nektar Therapeutics (Nasdaq:NKTR)., Results of a ... of,NKTR-061 (Inhaled Amikacin) to treat mechanically ventilated,patients ...
Cached Medicine Technology:Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at AUA Annual Meeting 2Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at AUA Annual Meeting 3Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at AUA Annual Meeting 4Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 2Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 3Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 4Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 5Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 6Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 7Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 8Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 9Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 10Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 11
The CALBIOTECH, INC. (CBI), Mumps IgM ELISA tests system is an enzyme linked immunosorbent assay (ELISA) for the detection of IgM class antibodies to Mumps in human serum or plasma....
... is comprised of the TEG analyzer and the ... picture of the formation and dissolution of the ... two systems. ,Haemoscope's TEG analyzer is the only ... the reliable and proven model developed by Prof. ...
With BareWire technology, the wire crosses the lesion first, independent of the filter and delivery catheter. All other actions, including filter placement and retrieval, balloon dilatations, and ste...
... is supported on NT / 2000 platforms. ... to effectively work in a multi-user, networked ... move comfortably to an enhanced level of ... improving the quality of patient care. , ...
Medicine Products: